EGFR and non-small cell lung carcinoma: Moreover, the CHRYSALIS study also demonstrated that amivantamab combined with lazertinib showed antitumor activity in the osimertinib-resistant setting, and the MARIPOSA study (NCT04487080) is ongoing to compare the efficacy and safety of amivantamab plus lazertinib with osimertinib alone as first-line treatment for EGFR-mutant NSCLC [212].